xslot

Alex Ovechkin is expected to miss 4 to 6 weeks with a broken left leg
DALLAS , Dec. 16, 2024 /PRNewswire/ -- Bestow , a leading technology company in the life insurance industry, has been named one of the Top 100 Financial Technology Companies of 2024 by The Financial Technology Report . This recognition highlights Bestow's innovative approach to modernizing life insurance and its commitment to delivering seamless, high-impact solutions. The Financial Technology Report annually highlights organizations redefining financial services with innovation, influence, and impact. Bestow's inclusion places it among industry leaders, underscoring its role in transforming how life insurance is provided. "This recognition is a testament to our team's relentless focus on creating a better way to offer life insurance," said Melbourne O'Banion, CEO and Co-Founder, Bestow. "Bestow plays a crucial role in driving rapid innovation within the industry, and I'm proud of our team's commitment to our mission." Bestow's proprietary platform removes traditional barriers in the life insurance process, offering a fully digital experience that eliminates the need for medical exams and lengthy paperwork. Its advanced technology enables businesses to quickly integrate life insurance solutions and products into their platforms, helping carriers increase customer growth and profitability. Since its inception, Bestow has been at the forefront of insurtech innovation, leveraging data science and AI, forging strategic partnerships, and developing scalable solutions that empower businesses and broaden access to life insurance. This leadership has solidified its position in the evolving financial technology sector. Earlier this year, Bestow was recognized as one of the Top 25 Insurtech Companies by The Financial Technology Report for its success in partnering with leading carriers to broaden the reach and impact of life insurance solutions. Additionally, CNBC honored Bestow as one of the world's leading insurtech companies of 2024. For more information about Bestow, visit: Bestow.com About Bestow Bestow is on a mission to increase financial stability for everyone. We partner with top life insurance carriers to deploy cutting-edge technology and data solutions that reduce costs, maximize efficiency, and drive growth by streamlining processes from origination and underwriting through administration. To learn more, visit Bestow.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/bestow-named-a-top-100-financial-technology-company-of-2024-302333006.html SOURCE Bestow Inc.
‘Woke = snob’: Sneering progressives treat the rest of us like half-witsMONTRÉAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Earth Alive Clean Technologies Inc. (TSXV: EAC - "Earth Alive” or the "Company”) today announced that it has obtained an order from the Superior Court of Québec (the " Court ”) extending the delay to file a proposal pursuant to the provisions of the Bankruptcy and Insolvency Act (Canada) (the " BIA ”) until January 30, 2025. This extension will allow the Company to complete, under the supervision of the Court and with the assistance of the Trustee, its ongoing sale and investment solicitation process (the " SISP "), in order to conclude a transaction with a view to maximizing the value of the Company's business and assets. The Company will provide further updates as developments regarding the notice of intention (" NOI ”) proceedings and the SISP warrant. A copy of the relevant information regarding the NOI proceedings and the SISP is available on the Trustee's website at the following address: https://www.raymondchabot.com/en/companies/public-records/earth-alive-clean-technologies-inc/ . Anyone interested in obtaining more information about the NOI proceedings or the SISP should contact the proposal trustee (Ayman Chaaban - [email protected] ) or the Company's legal counsel (Gabriel Lavery Lepage - [email protected] ). About Earth Alive Clean Technologies Inc. Earth Alive is a leader in the microbial technologies industry. Earth Alive's innovative products contribute to regenerative agriculture, natural dust suppression with minimal water use, and ecological, human-friendly industrial cleaning. For more information, please visit: https://earthalivect.com . For inquiries, please contact: Nikolaos Sofronis, CEO Phone: 438-316-3562 Email: [email protected]Countering terror — beyond labels Khawarij are notorious for extremist proclamations branding anyone who disagreed with their views as heretics During the past few weeks, terrorists affiliated with the TTP), Al-Qaeda, and the Islamic State of Khorasan Province (ISKP) have been referred to by Pakistani authorities as Khawarij. This term, rooted in early Islamic history (7th century), was used to describe a rebellious group that declared caliphs as infidels, rejected their authority, and perpetrated violence against mainstream Muslims. The Khawarij were notorious for their extremist proclamations, branding anyone who disagreed with their views as heretics and beyond the pale of the law. They believed that those who did not conform to their interpretation of religion were apostates and thus legitimate targets for violence. In support of their actions, they frequently cited the Quranic verse directing believers “to enjoin what is right and forbid what is wrong”. The Khawarij ideology has reappeared throughout Islamic history with cyclical regularity. They led numerous rebellions and continued to be a source of insurrection. Mainstream scholars consistently condemned them. Most Muslims today reject violence and terrorism, adhering to the Quran and various schools of Islamic law that forbid the killing of innocent civilians and law enforcement personnel. They uphold the belief that Islam’s central message is peace. In the present era, the influence of Khawarij ideology is evident in groups subscribing to the doctrines of the Taliban, Bin Laden, or Daesh. Thus, TTP, AQ, and ISKP can aptly be termed Neo-Kharijites. This discourse reinforces the rationale behind labeling these terrorists as Khawarij, as it strengthens the counter-narrative to the terrorists’ ideology. However, questions remain: does this measure, coupled with rhetorical promises and expressions of resolve to send terrorists to hell, suffice? Additionally, where is the comprehensive counter-narrative against terrorism and extremism, and how is it being disseminated to the public, particularly to disillusioned youth? The national counter-narrative available on the Nacta website primarily relies on the Paigham-e-Pakistan fatwa, which focuses on condemning acts of terrorism, including suicide bombings and other violent means, as being against the tenets of Islam. However, it fails to address broader aspects, such as Islam’s alignment with democratic principles and the concept of nation-states being compatible with Islamic teachings. It also does not emphasise that matters such as blasphemy, apostasy, and disbelief fall under the jurisdiction of the state and not individuals. The narrative is also silent on Islam’s teachings regarding peace, as well as its social and economic dimensions. Moreover, the propagation and publicity of the national counter-narrative against terrorism and extremism through electronic and print media remain inadequate. Religiously motivated acts of terrorism are predominantly concentrated in Khyber Pakhtunkhwa (KP), Quetta, and surrounding areas, where groups like TTP, AQ, and ISKP are active. These organisations aim to gain territorial control in the newly merged districts of the erstwhile Fata, with their primary objective being the establishment of an Islamic state or caliphate. Their main targets include law-enforcement agencies, Shias, minorities, political leaders, and political gatherings. In the rest of Balochistan, however, subversive activities are largely carried out by the Baloch Liberation Army (BLA) and other militant nationalist groups seeking the secession of the province from Pakistan. Their targets include security forces, individuals from other ethnic backgrounds, mine workers, goods transport vehicles, railway infrastructure, and Sui gas installations. According to Nacta, the alarming surge in terrorist acts across the country in 2024 saw 1,566 violent incidents resulting in the martyrdom of 925 law enforcement personnel (LEAs) and civilians by October. This marks a significant increase compared to the 1,284 incidents and 771 martyrdoms reported during the same period last year, reflecting a 22 percent rise in incidents and a 20 per cent increase in casualties. Of these, 60 per cent occurred in Khyber Pakhtunkhwa (KP) and 37 per cent in Balochistan, making these two provinces the most vulnerable to such acts. Exploiting the situation, terrorist organisations have resorted to illegal activities such as smuggling, extortion, and kidnapping for ransom to fund their operations. Pakistan’s counterterrorism efforts have been ongoing for decades, with varying degrees of success since 2001. Numerous military operations have been launched to combat terrorism, achieving reasonable results, but they have failed to develop into a comprehensive counterinsurgency strategy. Political instability and corruption have further undermined the effectiveness of the fragmented plans implemented so far. Combating insurgency and terrorism requires a multifaceted approach that combines kinetic and non-kinetic measures. The troubled regions of Khyber Pakhtunkhwa (KP) and Balochistan remain among the nation’s most impoverished areas. In KP, people demand the fulfillment of promises regarding development in the newly merged districts, rehabilitation of displaced populations, the revival of border trade, and freedom of movement. They also advocate for the police to take a leading role in countering insurgency and terrorism. In Balochistan, the foremost demand is genuine representation of the people in the provincial government, as opposed to the ever-increasing de facto power of the establishment. The state is accused of systematically neglecting their needs and exploiting their resources, which fuels feelings of betrayal and deprivation. Socioeconomic injustice and widespread discontent drive disillusioned youth toward subversive activities. The government’s harsh response to peaceful protests in Gwadar and other areas, coupled with the forced disappearances of many Baloch activists, has deepened distrust and strengthened support for separatist sentiments. In both provinces, external factors also contribute to the unrest. Rebel Baloch leaders maintain strong ties with India. A notable case is that of Indian naval officer Kulbhushan Jhadav, who was apprehended in Balochistan a few years ago on charges of espionage and terrorism. Additionally, Pakistani agencies have documented evidence of Indian intelligence agencies aiding the BLA, TTP, and other terrorist groups. The state’s policy of branding non-militant organisations like the Pashtun Tahafuz Movement (PTM) and the Baloch Yakjehti Committee (BYC) as enemy agents is profoundly misguided. Their demands call for sincere engagement, avoiding negative labeling and marginalisation. Failure to include them in constructive dialogue will only exacerbate existing tensions. To effectively combat insurgency and terrorism, intelligence-based kinetic operations must be improved by establishing robust mechanisms for intelligence sharing and coordination among various civilian and military agencies. Once areas are cleared of insurgents, the lead role should be handed over to the police, with support from paramilitary forces and the army, as practiced in most democracies. Gradually merging the tribal areas of KP and Punjab, along with the ‘B areas’ of Balochistan, into the mainstream administrative system would help eliminate insurgents’ hiding places and ensure uniform governance. In the non-kinetic domain, establishing bilateral border trade zones at crossing points along the Pakistan-Afghanistan border, modeled after the Gabd-Rimdan trade zone on the Pakistan-Iran border, could significantly boost local economies. Such zones, which facilitate trade in local currencies, generate government revenue through taxes and duties while creating employment opportunities. For instance, the yearly trade volume at the Pakistan-Iran border market is approximately Rs12.6 billion, contributing Rs2.5 billion in revenue and creating 5,000–7,000 jobs. Other critical measures include the development of infrastructure, improved health and education facilities in troubled regions, and reduced interference by military institutions in local affairs. Long-delayed madrassah reforms outlined in the revised National Action Plan should be implemented to cut off recruitment pipelines for terrorist organisations. Enlightened Islamic scholar Javed Ahmad Ghamdi has proposed making a minimum of intermediate-level general education mandatory before undertaking Dars-e-Nizami, the six-year course required to become an alim. Regarding Balochistan, there are “no simple solutions or quick fixes”, as noted by public policy specialist Rafiullah Kakar in a recent article. He argues that confidence-building measures (CBMs) could lay the groundwork for future political engagement. At a minimum, these CBMs should include ensuring genuine political representation, ending enforced disappearances, and reducing reliance on force. Such measures could pave the way for political reconciliation, without which, he warns, “the future of Balochistan looks bleak”. The writer is a retired inspector general of police and former caretaker home minister of Punjab.
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenThe Moravian Lovefeast is a unique worship experience held during the season of Advent each year at First Presbyterian Church. Always the first Sunday evening in December, this year’s service will be held on Dec. 1 at 6 p.m. This Christian fellowship has been a tradition at First Presbyterian Church for more than 40 years. During this service, everyone has the opportunity to enjoy music and song by gifted musicians and scripture readings by talented speakers. One of the highlights of the Moravian Lovefeast is the agape meal, which consists of hot, buttered yeast rolls and steaming mugs of coffee. This humble and heartwarming supper is served within the church by members of the congregation in traditional Moravian dress who invite the community to partake along with them. This exceptional service concludes with the congregational lighting of beeswax candles, which represent the purity of Christ. The candles are wrapped in red crepe paper ribbon symbolizing the blood of Jesus, which was voluntarily shed on the cross in atonement for sin. Children light the candles at the end of each pew one by one, each person lighting another’s candle until the entire room is aglow. As the early Christians met and broke bread together in token of their fellowship and love for Christ and each other, so the members of the First Presbyterian Church family have made it their custom to celebrate the birth of the Christ child by sharing with friends a simple meal, or “lovefeast” in the Moravian tradition. The name of the service is a literal translation of the New Testament word “agape.” A Lovefeast (not to be confused with communion) seeks to remove social barriers and strengthen the spirit of unity, goodwill, and brotherhood among all people. This special service incorporates a simple meal in order to serve God by loving each other and the community.
Company's first ultra-low power AI module will be commercially available for wearables and various other battery-powered on-device AI applications starting Q1 2025 SANTA CLARA, Calif. , Dec. 16, 2024 /PRNewswire/ -- Ambient Scientific, The AI Processor Company, announced today its first coin cell battery powered AI module, named the Sparsh-board, targeted for a variety of on-device AI applications such as human activity recognition, voice control, acoustic event detection and more capable of running on a coin cell battery for months of always-on AI operation. Equipped with motion sensors, a digital microphone, BLE module and several other components, the Sparsh module is an extremely powerful and versatile module to enable rapid prototyping of a vast array of battery-powered AI applications. "While traditional MCUs force an undesirable tradeoff between AI performance and power consumption, our ultra-low power AI processor GPX10 ushers a paradigm shift with our groundbreaking analog in-memory computing technology," said GP Singh, Founder and CEO of Ambient Scientific. Product makers can now enable highly accurate and diverse AI applications without compromising on AI performance, battery life, form factor, flexibility and more. Ambient Scientific's exhaustive software stack makes the development of AI applications easier than ever before with support for industry standard AI frameworks such as Tensorflow and keras and a continuously evolving homegrown compiler, capable of supporting essentially all the major types of neural networks. With various sample AI applications and algorithms included, developers can get begin developing AI applications within minutes of downloading our AmbiSense SDK . Current applications being worked on cut across industries, including predictive maintenance, AI-enabled medical devices, wearables, voice controlled toys and more. With increasing demand from product makers, enthusiasts, students and researchers alike, Ambient Scientific plans to launch several reference designs for battery-powered AI applications and similar form factor modules to enable rapid prototyping and fulfill its mission to make AI computing efficient, accessible and affordable for all. Meet Ambient Scientific at CES 2025 Ambient Scientific is excited to unveil its Sparsh AI module at CES 2025 with live demostrations of AI applications running on coin cell batteries such as Fall Detection, voice recognition and more. To explore potential synergies, attendees can schedule meetings CES 2025 with Ambient Scientific at. To learn more about Ambient Scientific, visit our booth at CES 2025 or download our press kit . About Ambient Scientific Ambient Scientific is a fabless semiconductor company pioneering AI hardware and software design to create next-generation low-power processors for edge and on-device AI applications. With a team comprised of Ex-Sun Microsystems, Intel, Broadcom and Google professionals, Ambient Scientific is committed to bringing the power of AI to all, through cutting edge hardware and software products. To learn more about its products, visit www.ambientscientific.ai and follow Ambient Scientific on LinkedIn . Click here for more details about our booth at: https://ces25.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=0013A00001egpuFQAQ . View original content to download multimedia: https://www.prnewswire.com/news-releases/ambient-scientific-unveils-first-ever-ai-module-powered-by-a-coin-cell-battery-302332996.html SOURCE Ambient Scientific, Inc.
The Salvation Army's Annual Red Kettle Campaign Launches With the Help of the Dallas Cowboys, Country Star Lainey Wilson, and Special Guest
Idaho lawmakers look toward anti-DEI legislation, accreditation standards
Why Tesla Stock Jumped Again Today
ECU CB Shavon Revel Jr. declares for NFL draft
DALLAS , Dec. 16, 2024 /PRNewswire/ -- Bestow , a leading technology company in the life insurance industry, has been named one of the Top 100 Financial Technology Companies of 2024 by The Financial Technology Report . This recognition highlights Bestow's innovative approach to modernizing life insurance and its commitment to delivering seamless, high-impact solutions. The Financial Technology Report annually highlights organizations redefining financial services with innovation, influence, and impact. Bestow's inclusion places it among industry leaders, underscoring its role in transforming how life insurance is provided. "This recognition is a testament to our team's relentless focus on creating a better way to offer life insurance," said Melbourne O'Banion, CEO and Co-Founder, Bestow. "Bestow plays a crucial role in driving rapid innovation within the industry, and I'm proud of our team's commitment to our mission." Bestow's proprietary platform removes traditional barriers in the life insurance process, offering a fully digital experience that eliminates the need for medical exams and lengthy paperwork. Its advanced technology enables businesses to quickly integrate life insurance solutions and products into their platforms, helping carriers increase customer growth and profitability. Since its inception, Bestow has been at the forefront of insurtech innovation, leveraging data science and AI, forging strategic partnerships, and developing scalable solutions that empower businesses and broaden access to life insurance. This leadership has solidified its position in the evolving financial technology sector. Earlier this year, Bestow was recognized as one of the Top 25 Insurtech Companies by The Financial Technology Report for its success in partnering with leading carriers to broaden the reach and impact of life insurance solutions. Additionally, CNBC honored Bestow as one of the world's leading insurtech companies of 2024. For more information about Bestow, visit: Bestow.com About Bestow Bestow is on a mission to increase financial stability for everyone. We partner with top life insurance carriers to deploy cutting-edge technology and data solutions that reduce costs, maximize efficiency, and drive growth by streamlining processes from origination and underwriting through administration. To learn more, visit Bestow.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/bestow-named-a-top-100-financial-technology-company-of-2024-302333006.html SOURCE Bestow Inc.
Ambient Scientific unveils first ever AI module powered by a coin cell battery
Island baseball and soccer orgainations team up for strategic partnershipNasdaq Reports November 2024 Volumes